Please assess the completion status of the following clinical trial:

Trial Title: Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* renal transplant within last 3 months~* serum phosphorus less than 2.0 mg/dl~* serum creatinine less than 2.0 mg/dl~Exclusion Criteria:~* sensitivity to cinacalcet~* use of amitryptiline, desipramine, itraconazole, ketoconazole~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cincalcet (Type: ACTIVE_COMPARATOR): cinacalcet will be titrated as needed to achieve serum phosphorus of \> 2.5 mg/dl randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at \~ 2.5 mg/l.
- Control (Type: PLACEBO_COMPARATOR): subjects will receive placebo pill titrated as needed to achieve phosphorus \> 2.5 mg/dl.~randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at \~ 2.5 mEq/l.

Based on this trial design, predict the completion outcome and termination type (if applicable).